Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Reference Intervals for Sonoclot Analysis in Chinese

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Zhenlu Zhang, Wuhan Asia Heart Hospital
ClinicalTrials.gov Identifier:
NCT01759433
First received: November 29, 2012
Last updated: December 28, 2013
Last verified: December 2013
  Purpose

The reference intervals for Sonoclot Analysis may be different between Chinese and American. So far, no reference interval has been established in Chinese for Sonoclot Analysis. This study is going to establish the first Chinese reference intervals for Sonoclot Analysis and test whether they are different from American reference intervals.


Condition
Cardiovascular Diseases

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Reference Ranges for Sonoclot Analysis in Chinese

Further study details as provided by Wuhan Asia Heart Hospital:

Primary Outcome Measures:
  • The reference intervals for sonoclot analysis in Chinese [ Time Frame: 3 month ] [ Designated as safety issue: No ]
    whether Chinese reference intervals are different from Caucasian reference intervals.


Biospecimen Retention:   None Retained

2.7 mL citrated blood.


Enrollment: 135
Study Start Date: December 2012
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Chinese healthy adults aged 18 and older

Criteria

Inclusion Criteria:

  • Aged 18 and older
  • Han ethnic

Exclusion Criteria:

  • Renal dysfunction
  • Liver disorders
  • Known coagulation disorders
  • Patients taking medications in the last month
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01759433

Locations
China, Hubei
Wuhan Asia Heart hospital
Wuhan, Hubei, China, 430022
Sponsors and Collaborators
Wuhan Asia Heart Hospital
  More Information

No publications provided

Responsible Party: Zhenlu Zhang, Director of the clinical laboratory, Wuhan Asia Heart Hospital
ClinicalTrials.gov Identifier: NCT01759433     History of Changes
Other Study ID Numbers: SCWH001
Study First Received: November 29, 2012
Last Updated: December 28, 2013
Health Authority: China: Ministry of Health

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on November 25, 2014